Miglitol and Ranitidine Interaction
Drug interaction information between Miglitol and Ranitidine.
Miglitol and Ranitidine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Miglitol and Ranitidine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Miglitol reduces how much ranitidine your body absorbs, which can make the medicine less effective.
What To Do
Tell your doctor if your stomach symptoms do not improve while taking both drugs.
FDA Label Information
Other healthy volunteer studies have demonstrated that miglitol may significantly reduce the bioavailability of ranitidine and propranolol by 60% and 40%, respectively.
Miglitol Also Interacts With
- Metformin minor
- Propranolol minor
- Warfarin minor
- Nifedipine minor
- Glyburide minor
Ranitidine Also Interacts With
- Risperidone major
- Theophylline major
- Valproate major
- Midazolam moderate
- Clonazepam minor
Frequently Asked Questions
Can I take Miglitol and Ranitidine together?
This is a minor interaction. Tell your doctor if your stomach symptoms do not improve while taking both drugs.
How serious is the interaction between Miglitol and Ranitidine?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Miglitol and Ranitidine interact?
Miglitol reduces how much ranitidine your body absorbs, which can make the medicine less effective.
Understanding the Miglitol and Ranitidine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Miglitol belongs to the Alpha-Glucosidase Inhibitor class and Ranitidine belongs to the H2 Receptor Antagonist class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Miglitol reduces how much ranitidine your body absorbs, which can make the medicine less effective. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Miglitol has 7 total documented interactions on file in this dataset, and Ranitidine has 15. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Tell your doctor if your stomach symptoms do not improve while taking both drugs. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Miglitol or Ranitidine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.